CMS proposes to Withdraw Trump Era Most Favored Nation (MFN) Drug Pricing Rule
FDA Law
AUGUST 10, 2021
That proposal was withdrawn by the Trump HHS, but the notion of international reference pricing was subsequently incorporated in an October 2018 HHS Advance Notice of Proposed Rulemaking (ANPR) (see our post here ). Use of international reference pricing as a target for Medicare to negotiate prices with drug manufacturers appears in H.R.
52 
Let's personalize your content